Molecuar Sub-typing of Prostate Cancer Based on Recurrent Gene Fusions

基于复发基因融合的前列腺癌分子分型

• 批准号: 7752773
• 负责人: ARUL M CHINNAIYAN
• 金额: $ 25.65万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7752773
• 关键词: Acute Myelocytic Leukemia; Adjuvant; American; American Cancer Society; Androgens; Basic Science; Behavior; Bioinformatics; Biological; Biological Markers; Biopsy; Biopsy Specimen; Cancer Patient; Categories; Cessation of life; Clinical; Clinical Data; Clinical Markers; Collaborations; Complement; Complementary DNA; Country; Data; Data Analyses; Data Set; Development; Diagnosis; Disease; ETV1 gene; ETV4 gene; EZH2 gene; Effectiveness; Elderly; Family; Family member; Fluorescent in Situ Hybridization; Funding; Gene Fusion; Genitourinary system; Gleason Grade for Prostate Cancer; Goals; Grant; Hematologic Neoplasms; Immunohistochemistry; Indolent; Intervention; Legal patent; Link; Localized Disease; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Metastatic Prostate Cancer; Metric; Michigan; Modeling; Molecular; Molecular Cytogenetics; Molecular Profiling; Nature; Needle biopsy procedure; Newly Diagnosed; Operative Surgical Procedures; Outcome; Pathology; Patient observation; Patients; Prostate; Prostatectomy; Prostatic Neoplasms; Publications; Publishing; Radiation; Radical Prostatectomy; Recurrence; Regulatory Element; Reproduction spores; Research Personnel; Role; Science; Series; Specimen; Staging; System; TMPRSS2 gene; Tissue Microarray; Tissues; Transcript; Universities; Validation; Variant; Work; base; cancer gene expression; cohort; follow-up; gene discovery; hepsin; improved; leukemia/lymphoma; male; member; men; novel; pre-clinical; prognostic; prognostic indicator; proto-oncogene protein pim-1; public health relevance; success; therapeutic target; tool; training project; transcription factor; tumor progression

DESCRIPTION (provided by applicant): Employing a bioinformatics approach to analyze prostate cancer gene expression profiles, we identified recurrent gene fusions/translocations in the majority of prostate cancers (Tomlins et al, Science 2005). Specifically, we identified the androgen regulatory elements of TMPRSS2 fused to the members of the ETS family of transcription factors including ERG, ETV1, ETV4 and ETV5. Analogous to hematological malignancies, gene fusions/translocations identified in prostate cancer may represent pathognomonic biomarkers and molecular sub-types of disease. In this application, we plan to focus our efforts on characterizing this new class of gene fusion biomarkers. Preliminary work done by our group and others suggest that molecular subtypes as well as transcript variants of gene fusions may be associated with clinical sub-types of prostate cancer. The central hypothesis of this application is that molecular sub-types based on gene fusions and variants will be useful predictors of the aggressive potential of clinically localized prostate cancer and thus guide treatment. Given this, we propose the following Aims: Specific Aim 1: Discovery and nomination of novel molecular sub-types of prostate cancer. Specific Aim 2: Characterize associations of molecular sub-types of prostate cancer with clinical outcome and/or aggressiveness of disease in a radical prostatectomy cohort. Specific Aim 3. Characterize associations of molecular sub-types of prostate cancer with clinical outcome and/or aggressiveness of disease using prostate needle biopsy samples. PUBLIC HEALTH RELEVANCE: Project Narrative: The discovery of genes fused together is a major advancement in the understanding of prostate cancer. This proposal is about using these "gene fusions" to identify prognostic categories to improve approaches to the treatment of prostate cancer patients.

描述（由申请人提供）：采用生物信息学方法分析前列腺癌基因表达谱，我们鉴定了大多数前列腺癌中的复发性基因融合/易位（Tomlins et al，Science 2005）。具体而言，我们鉴定了TMPRSS 2的雄激素调节元件融合到ETS家族的转录因子的成员，包括ERG、ETV 1、ETV 4和ETV 5。与血液恶性肿瘤类似，在前列腺癌中鉴定的基因融合/易位可能代表疾病的特异性生物标志物和分子亚型。在本申请中，我们计划集中精力表征这类新的基因融合生物标志物。我们小组和其他人所做的初步工作表明，分子亚型以及基因融合的转录变体可能与前列腺癌的临床亚型有关。本申请的中心假设是，基于基因融合和变异的分子亚型将是临床定位的前列腺癌的侵袭潜力的有用预测因子，从而指导治疗。鉴于此，我们提出了以下目标：具体目标1：发现和命名前列腺癌的新分子亚型。具体目标二：在根治性前列腺切除术队列中描述前列腺癌分子亚型与临床结局和/或疾病侵袭性的相关性。具体目标3。使用前列腺穿刺活检样本表征前列腺癌分子亚型与临床结果和/或疾病侵袭性的相关性。公共卫生相关性：项目叙述：基因融合在一起的发现是对前列腺癌认识的重大进步。这项提案是关于使用这些“基因融合”来确定预后类别，以改善前列腺癌患者的治疗方法。